Nanosonics (NAN) Stock Price, News & Analysis

Company Overview

Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories, as well as research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; Nanosonics AuditPro, an infection control workflow compliance management; Trophon EPR for mitigating the risk of exposure to toxic chemicals; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 740,249 shs
• Average Volume: N/A
• Market Capitalization: $1.02 billion
• P/E Ratio: 78.25
• Dividend Yield: 8.00%
• Price Target: N/A
• Consensus Rating: N/A

NAN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Nanosonics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanosonics investors own include Nanosonics (NNCSF), Calix (CXL), Insignia Financial (IFL), Bubs Australia (BUB), EML Payments (EML), Isracann Biosciences (ISCNF) and Audentes Therapeutics (BOLD).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: Financial Services
• Current Symbol: ASX:NAN
• CUSIP: N/A
• CIK: N/A
• Web: www.nanosonics.com.au
• Phone: 61 2 8063 1600
• Fax: N/A
• Employees: 482
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A$0.04
• Trailing P/E Ratio: 78.25
• Forward P/E Ratio: N/A
• P/E Growth: 2.74
• Net Income: $12.97 million
• Net Margins: 7.58%
• Pretax Margin: N/A
• Return on Equity: 7.25%
• Return on Assets: 2.34%

Debt

• Debt-to-Equity Ratio: 5.11
• Current Ratio: 6.16
• Quick Ratio: 4.22

Sales & Book Value

• Annual Sales: $170.01 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 25.90
• Book Value: A$0.60 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 303,370,000
• Free Float: N/A
• Market Cap: $1.02 billion
• Optionable: Not Optionable
• Beta: 1.55